将法国预后评分应用于接受5-氮杂胞苷治疗的国际预后评分系统中危-2或高危骨髓增生异常综合征患者，能够预测总生存期和缓解率。 - Suppr

Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response.

作者信息

Breccia Massimo, Loglisci Giuseppina, Cannella Laura, Finsinger Paola, Mancini Marco, Serrao Alessandra, Santopietro Michelina, Salaroli Adriano, Alimena Giuliana

出版信息

Leuk Lymphoma. 2012 May;53(5):985-6. doi: 10.3109/10428194.2011.643408. Epub 2012 Jan 11.

DOI:10.3109/10428194.2011.643408

PMID:22112007

Abstract

摘要

相似文献

Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response.将法国预后评分应用于接受5-氮杂胞苷治疗的国际预后评分系统中危-2或高危骨髓增生异常综合征患者，能够预测总生存期和缓解率。

Leuk Lymphoma. 2012 May;53(5):985-6. doi: 10.3109/10428194.2011.643408. Epub 2012 Jan 11.

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.比较阿扎胞苷治疗骨髓增生异常综合征患者中修订后的国际预后评分系统和法国预后评分系统的预后预测价值。

Br J Haematol. 2014 Aug;166(3):352-9. doi: 10.1111/bjh.12884. Epub 2014 Apr 9.

Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.比较各种标准在预测接受阿扎胞苷治疗的骨髓增生异常综合征患者的治疗反应和预后中的作用。

Ann Hematol. 2010 Jan;89(1):15-23. doi: 10.1007/s00277-009-0771-1. Epub 2009 Jun 19.

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.用于预测接受氮杂核苷治疗的高危骨髓增生异常综合征患者预后的风险分层工具比较

Leukemia. 2016 Mar;30(3):649-57. doi: 10.1038/leu.2015.283. Epub 2015 Oct 14.

Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.阿扎胞苷5天方案治疗高危骨髓增生异常综合征患者的疗效与安全性。

Eur J Haematol. 2016 Sep;97(3):228-31. doi: 10.1111/ejh.12709. Epub 2016 Jan 3.

Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.西班牙骨髓增生异常综合征登记处纳入的年龄≥75岁患者接受阿扎胞苷治疗的结果。

Leuk Lymphoma. 2014 Jun;55(6):1300-3. doi: 10.3109/10428194.2013.834532. Epub 2013 Sep 16.

Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.阿扎胞苷在高危骨髓增生异常综合征中的实际应用：专家小组意见。

Leuk Res. 2010 Nov;34(11):1410-6. doi: 10.1016/j.leukres.2010.05.021. Epub 2010 Jul 6.

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.阿扎胞苷治疗骨髓增生异常综合征（MDS）患者：德国 MDS 研究组的实用建议。

Ann Hematol. 2010 Sep;89(9):841-50. doi: 10.1007/s00277-010-1015-0. Epub 2010 Jun 22.

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.高危骨髓增生异常综合征和急性髓系白血病患者序贯使用阿扎胞苷和来那度胺：一项单臂1/2期研究。

Lancet Haematol. 2015 Jan;2(1):e12-20. doi: 10.1016/S2352-3026(14)00026-X. Epub 2014 Dec 22.

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.阿扎胞苷治疗未选择高危骨髓增生异常综合征的疗效：来自西班牙登记处的数据。

Leukemia. 2015 Sep;29(9):1875-81. doi: 10.1038/leu.2015.115. Epub 2015 May 6.

引用本文的文献

More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.多即是少，少即是多，还是这真的重要？阿扎胞苷给药方案对骨髓增生异常综合征患者预后影响的奇特案例。

BMC Hematol. 2018 Feb 1;18:4. doi: 10.1186/s12878-018-0095-2. eCollection 2018.

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia.阿扎胞苷方案治疗骨髓增生异常综合征和急性髓系白血病的系统评价

BMC Hematol. 2018 Jan 31;18:3. doi: 10.1186/s12878-017-0094-8. eCollection 2018.

Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.阿扎胞苷：在骨髓增生异常综合征和急性髓系白血病中的综述。

Drugs. 2016 May;76(8):889-900. doi: 10.1007/s40265-016-0585-0.

Leukemia. 2016 Mar;30(3):649-57. doi: 10.1038/leu.2015.283. Epub 2015 Oct 14.

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.TET2突变可预测骨髓增生异常综合征患者对去甲基化药物的反应。

Blood. 2014 Oct 23;124(17):2705-12. doi: 10.1182/blood-2014-06-582809. Epub 2014 Sep 15.

Stopping higher-risk myelodysplastic syndrome in its tracks.在早期阶段阻止高风险骨髓增生异常综合征。

Curr Hematol Malig Rep. 2014 Dec;9(4):421-31. doi: 10.1007/s11899-014-0234-1.

Br J Haematol. 2014 Aug;166(3):352-9. doi: 10.1111/bjh.12884. Epub 2014 Apr 9.

Predicting response to epigenetic therapy.预测表观遗传学治疗的反应。

J Clin Invest. 2014 Jan;124(1):47-55. doi: 10.1172/JCI69737. Epub 2014 Jan 2.

Current therapy of myelodysplastic syndromes.骨髓增生异常综合征的当前治疗。

Blood Rev. 2013 Sep;27(5):243-59. doi: 10.1016/j.blre.2013.07.003. Epub 2013 Jul 27.

Concise drug review: azacitidine and decitabine.简明药物评论：阿扎胞苷和地西他滨。

Oncologist. 2013;18(5):619-24. doi: 10.1634/theoncologist.2012-0465. Epub 2013 May 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献